Back to results
US 2022/0175909 A1Published application
Influenza vaccine composition based on novel nucleic acid
AssigneeNa Vaccine Institute
InventorsMee Hyein KIM, Jin Soo SHIN, Dong Ho KIM, Eui Ho KIM, Myung Soo KANG, Ye Jin JANG
Life of this patent
Estimating the term…
Abstract
Provided is an influenza vaccine composition based on a novel ribonucleic acid having a dual function of serving as an immunity-boosting agent and capturing antigens.
Claims20
A vaccine composition for preventing or treating influenza virus infection, the vaccine composition comprising a hetero-structured ribonucleic acid (hsRNA) comprising a double-stranded ribonucleic acid (dsRNA) and single-stranded ribonucleic acids (ssRNAs);
- and a human influenza virus antigen,
- wherein the dsRNA is formed by complementary binding between a first single-stranded RNA and a second single-stranded RNA which are complementary to each other, and the ssRNAs are linked at both the 3′-ends of the dsRNA, respectively,
- wherein the hsRNA has 140 nt to 1682 nt in length,
- wherein the dsRNA region has 106 nt to 1648 nt in length, and
- wherein the ssRNA region has 1 to 10 nt in length.
2 more elements
Dependencies are inferred from the claim text.